search
Back to results

Oral Naltrexone In Pediatric Eating Disorders (ONPED)

Primary Purpose

Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical

Status
Enrolling by invitation
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Naltrexone Hydrochloride
Control
Sponsored by
Rosemary Claire Roden
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anorexia Nervosa/Bulimia

Eligibility Criteria

13 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Ages 13-25 (inclusive)
  • Any sex
  • Diagnoses of anorexia nervosa binge-purge subtype, bulimia nervosa, purging disorder, or atypical anorexia nervosa with bingeing or purging behaviors according to the Diagnostic and Statistical Manual version 5 diagnostic criteria
  • Electing to participate in child or adult partial hospitalization program for eating disorder treatment at MSHMC

The diagnostic criteria for anorexia nervosa, binge-purge subtype, are:

A. Restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. Significantly low weight is defined as a weight that is less than minimally normal or, for children and adolescents, less than minimally expected.

B. Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, even though at a significantly low weight.

C. Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight D. During the last three months the individual has engaged in recurrent episodes of binge eating or purging behaviour (i.e. self-induced vomiting, or the misuse of laxatives, diuretics, or enemas).19 E. A diagnosis of atypical anorexia nervosa can be made when the body weight is normal or high If these patients engage in bingeing or purging behaviors as defined in anorexia nervosa, binge-purge subtype, they are eligible for inclusion in this study

The diagnostic criteria for bulimia nervosa are:

A. Recurrent episodes of binge eating. An episode of binge eating is characterized by

B. both:

i. Eating in a discrete period of time (e.g. within any 2 hour period), an amount of food that is definitely larger than what most individuals would eat in a similar period of time under similar circumstances; ii. A sense of lack of control over eating during the episodes (e.g. a feeling that one cannot stop eating or control what or how much one is eating.

C. Recurrent inappropriate compensatory behaviors to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting; or excessive exercise.

D. The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for 3 months.

E. Self-evaluation is unduly influenced by body shape and weight. F. The disturbance does not occur exclusively during episodes of anorexia nervosa.

• The diagnostic criteria for purging disorder are: recurrent purging behavior to influence weight or shape (e.g. self-induced vomiting; misuse of laxatives, diuretics, or other medications) in the absence of binge eating.

Exclusion Criteria:

  • Diagnosis of intellectual disability
  • History of known genetic or neurologic disease
  • Need for treatment with opioid painkillers
  • Weight <25kg
  • Inability to swallow pills
  • Lack of proficiency in written or spoken English
  • Urine drug screen positive for opioids at enrollment
  • Positive serum pregnancy test at enrollment
  • Lactation
  • Elevation of three times the upper limit of normal for age in either alanine aminotransferase (ALT) or asparagine aminotransferase (AST).High risk of suicide at enrollment on Columbia Suicide Severity Rating Scale (C-SSRS, for participants age 18-25) or Ask Suicide Screening Questions (ASQ, participants age 13 to 17)

Sites / Locations

  • Penn State Milton S. Hershey Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Intervention

Control

Arm Description

Oral naltrexone, to start as 25mg for three days then 50mg a day for 6 weeks. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler

Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for six weeks

Outcomes

Primary Outcome Measures

ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
ED-15 score
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.

Secondary Outcome Measures

Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Eating Disorder Examination Questionnaire score (EDE-Q)
EDE-Q is an evidence-based metric of eating disorder severity
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Patient Health Questionnaire score (PHQ-9)
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Generalized Anxiety Disorder Screener score (GAD-7)
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
evidence-based metric of urge to self-harm
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Evidence-based metric of impulsivity
Rate of weight restoration
For participants who need to restore weight, will evaluate the rate of weight gain in care
Rate of weight restoration
For participants who need to restore weight, will evaluate the rate of weight gain in care
Need For Higher Level of Care
Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility
Need For Higher Level of Care
Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility

Full Information

First Posted
July 19, 2021
Last Updated
August 15, 2023
Sponsor
Rosemary Claire Roden
Collaborators
Children's Miracle Network
search

1. Study Identification

Unique Protocol Identification Number
NCT05073679
Brief Title
Oral Naltrexone In Pediatric Eating Disorders
Acronym
ONPED
Official Title
A Double-Blind Placebo-Controlled Evaluation of Effectiveness of Oral Naltrexone in Management of Adolescent Eating Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 22, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Rosemary Claire Roden
Collaborators
Children's Miracle Network

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to evaluate the effectiveness of oral naltrexone tablets in pediatric and adolescent eating disorders, in particular anorexia nervosa and bulimia nervosa, as compared to placebo. Study participants will be patients in a partial hospitalization program or intensive outpatient program for eating disorder.
Detailed Description
Subjects participating in this study will receive routine care for eating disorder at a partial hospitalization (PHP) level of care at MSHMC. In PHP, all patients have weekly medical screening visits for the duration of their time in care, as well as weekly individual therapy sessions, individual dietician sessions, and psychiatry appointments. They have supervised meals and numerous group therapy sessions. Every three weeks, patients in PHP complete a battery of mood and eating disorder indices including those evaluated in this study; participants in this study will complete an additional two surveys with this routine battery. Participants in this study will have no alterations in their routine eating disorder care outside of study article use and these additional surveys. Subjects will be enrolled at their first visit for eating disorder programming at child or adult partial hospitalization (PHP) programming at MSHMC adolescent medicine eating disorders clinic. Informed consent/assent will be obtained as described above. The subject will be provided with oral naltrexone or placebo weekly from the MSHMC research pharmacy. Subjects will be given one weeks' worth of medication at a time. Subjects will be randomized at enrollment to receive either study drug (naltrexone) or placebo. Participants or parents of minor participants will be provided study drug or placebo following completion of urine drug screen and consent/assent. Patients will take the medication daily for six weeks. For subjects who are enrolled in child PHP and who eat meals with parents, the families may choose to administer study drug during meals at programming. For adult patients enrolled in adult programming, subjects may choose to self-administer the medication. On their first contact with PHP, all patients in Child PHP complete various eating disorder indices as a part of routine care, including the ED-15, EDE-Q, RCMAS, CDI, GAD-7, and PHQ-9. This battery of indices is repeated every 3 weeks while a patient is in programming. For those who are enrolled in this study, they will complete their routine indices, in addition they will also complete the BIS/BAS and the ABUSI at enrollment and at weeks 3, 6, and 9 (after completion of medication) while in programming. Participants will receive routine eating disorder care while in PHP. Patients in Adult PHP typically complete a different inventory every three weeks. If a patient choses to participate in this study they will be asked to complete the same surveys as participants in Child PHP, and they will receive the same amount and type of compensation. Six months after enrollment, subjects will be sent copies of ED-15, EDE-Q, GAD-7, PHQ-9, BIS/BAS, and ABUSI indices either in an in-person medical appointment or via RedCap to complete. If the patient returns for medical follow-up between 5 and 7 months after enrollment, their height, weight, and body mass index will also be recorded to determine if weight restoration was maintained. At initial contact with the eating disorders clinic, all patients receive an initial battery of laboratory tests as a part of the standard of care for eating disorder. These tests include liver function assays and transaminase levels.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anorexia Nervosa/Bulimia, Anorexia in Adolescence, Anorexia Nervosa, Atypical, Anorexia Nervosa, Binge Eating/Purging Type, Purging (Eating Disorders), Impulsive Behavior, Eating Disorders, Bulimia Nervosa, Eating Disorders in Adolescence

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Model Description
double-blind, placebo controlled randomized clinical trial
Masking
ParticipantCare ProviderInvestigator
Masking Description
The Penn State Health IDS pharmacy will purchase Naltrexone 50mg tablets from a pharmaceutical wholesaler. The IDS pharmacy will purchase gelatin capsules and USP grade methylcellulose from a pharmacy supplier to be used for compounding the active and placebo capsules. For the active Naltrexone 50mg capsules, a Naltrexone 50mg tablet will be placed in an empty gelatin capsule with methylcellulose filler. The placebo capsules will be empty gelatin capsules filled with Methylcellulose. Participants will be randomized using redcap at enrollment to either study article or placebo, and neither investigators nor care providers will be aware of which article the participants receive.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Experimental
Arm Description
Oral naltrexone, to start as 25mg for three days then 50mg a day for 6 weeks. Oral naltrexone generic tabs will be blinded in opaque gelatin capsules with methylcellulose filler
Arm Title
Control
Arm Type
Placebo Comparator
Arm Description
Opaque gelatin capsules with methylcellulose filler, taken by mouth once a day for six weeks
Intervention Type
Drug
Intervention Name(s)
Naltrexone Hydrochloride
Intervention Description
25mg x 3 days then 50mg a day thereafter
Intervention Type
Other
Intervention Name(s)
Control
Intervention Description
Methylcellulose and gelatin capsule only
Primary Outcome Measure Information:
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: enrollment
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: one week
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: three week
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: six weeks
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: nine weeks (last week of treatment)
Title
ED-15 score
Description
ED-15 is an evidenced-based metric of eating disorder symptom severity and frequency.
Time Frame
Time Frame: Measured at the following timepoints: 6 months after enrollment
Secondary Outcome Measure Information:
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: enrollment
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: one week
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: three weeks
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: six weeks
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: nine weeks (last week of treatment)
Title
Eating Disorder Examination Questionnaire score (EDE-Q)
Description
EDE-Q is an evidence-based metric of eating disorder severity
Time Frame
Measured at the following timepoints: 6 months after enrollment
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: enrollment
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: one week
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: three weeks
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: six weeks
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: nine weeks (last week of treatment)
Title
Patient Health Questionnaire score (PHQ-9)
Description
Evidence-based metric of depression, min = 0, max= 27, higher scores indicate more severe depression
Time Frame
Measured at the following timepoints: 6 months after enrollment
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: enrollment
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: one week
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: three weeks
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: six weeks
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: nine weeks (last week of treatment)
Title
Generalized Anxiety Disorder Screener score (GAD-7)
Description
evidence-based metric of anxiety, min=0, max=21, higher scores indicate more severe anxiety
Time Frame
Measured at the following timepoints: 6 months after enrollment
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: enrollment
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: one week
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: three weeks
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: six weeks
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: nine weeks (last week of treatment)
Title
Alexian Brothers Urge to Self-Injure Scale (ABUSI)
Description
evidence-based metric of urge to self-harm
Time Frame
Measured at the following timepoints: 6 months after enrollment
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: enrollment
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: one week
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: three weeks
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: six weeks
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: nine weeks (last week of treatment)
Title
Behavioral Inhibition System/Behavioral Activation System score (BIS/BAS)
Description
Evidence-based metric of impulsivity
Time Frame
Measured at the following timepoints: 6 months after enrollment
Title
Rate of weight restoration
Description
For participants who need to restore weight, will evaluate the rate of weight gain in care
Time Frame
Will evaluate total rate of weight restoration via chart review at the end of the study
Title
Rate of weight restoration
Description
For participants who need to restore weight, will evaluate the rate of weight gain in care
Time Frame
Will evaluate total rate of weight restoration via chart review 6 months after enrollment
Title
Need For Higher Level of Care
Description
Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility
Time Frame
Will evaluate total rate of weight restoration via chart review at the end of the study
Title
Need For Higher Level of Care
Description
Need to leave the current level of care (where the study is being conducted) to go to a residential, inpatient, or hospital facility
Time Frame
Will evaluate total rate of weight restoration via chart review 6 months after enrollment
Other Pre-specified Outcome Measures:
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
enrollment for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 1 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 2 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 3 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 4 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 5 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 6 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 7 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 8 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 9 for patients age 17 or older
Title
Columbia Suicide Severity Rating Scale (CSSRS)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
6 months after enrollment for patients age 17 or older
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
enrollment for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 1 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 2 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 3 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 4 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 5 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 6 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 7 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 8 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
week 9 for patients age 16 or younger
Title
Ask Suicide Screening Questions (ASQ)
Description
Evidence-based metric evaluating for presence of suicidal ideation and severity
Time Frame
6 months after enrollment for patients age 16 or younger

10. Eligibility

Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Ages 13-25 (inclusive) Any sex Diagnoses of anorexia nervosa binge-purge subtype, bulimia nervosa, purging disorder, or atypical anorexia nervosa with bingeing or purging behaviors according to the Diagnostic and Statistical Manual version 5 diagnostic criteria Electing to participate in child or adult partial hospitalization program for eating disorder treatment at MSHMC The diagnostic criteria for anorexia nervosa, binge-purge subtype, are: A. Restriction of energy intake relative to requirements, leading to a significantly low body weight in the context of age, sex, developmental trajectory, and physical health. Significantly low weight is defined as a weight that is less than minimally normal or, for children and adolescents, less than minimally expected. B. Intense fear of gaining weight or of becoming fat, or persistent behavior that interferes with weight gain, even though at a significantly low weight. C. Disturbance in the way in which one's body weight or shape is experienced, undue influence of body weight or shape on self-evaluation, or persistent lack of recognition of the seriousness of the current low body weight D. During the last three months the individual has engaged in recurrent episodes of binge eating or purging behaviour (i.e. self-induced vomiting, or the misuse of laxatives, diuretics, or enemas).19 E. A diagnosis of atypical anorexia nervosa can be made when the body weight is normal or high If these patients engage in bingeing or purging behaviors as defined in anorexia nervosa, binge-purge subtype, they are eligible for inclusion in this study The diagnostic criteria for bulimia nervosa are: A. Recurrent episodes of binge eating. An episode of binge eating is characterized by B. both: i. Eating in a discrete period of time (e.g. within any 2 hour period), an amount of food that is definitely larger than what most individuals would eat in a similar period of time under similar circumstances; ii. A sense of lack of control over eating during the episodes (e.g. a feeling that one cannot stop eating or control what or how much one is eating. C. Recurrent inappropriate compensatory behaviors to prevent weight gain, such as self-induced vomiting; misuse of laxatives, diuretics, or other medications; fasting; or excessive exercise. D. The binge eating and inappropriate compensatory behaviors both occur, on average, at least once a week for 3 months. E. Self-evaluation is unduly influenced by body shape and weight. F. The disturbance does not occur exclusively during episodes of anorexia nervosa. • The diagnostic criteria for purging disorder are: recurrent purging behavior to influence weight or shape (e.g. self-induced vomiting; misuse of laxatives, diuretics, or other medications) in the absence of binge eating. Exclusion Criteria: Diagnosis of intellectual disability History of known genetic or neurologic disease Need for treatment with opioid painkillers Weight <25kg Inability to swallow pills Lack of proficiency in written or spoken English Urine drug screen positive for opioids at enrollment Positive serum pregnancy test at enrollment Lactation Elevation of three times the upper limit of normal for age in either alanine aminotransferase (ALT) or asparagine aminotransferase (AST).High risk of suicide at enrollment on Columbia Suicide Severity Rating Scale (C-SSRS, for participants age 18-25) or Ask Suicide Screening Questions (ASQ, participants age 13 to 17)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rosemary C Roden, MD
Organizational Affiliation
PennState Health Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No participant data is planned to be shared at the moment to protect patient privacy, as participants are all enrolled in a partial hospitalization program for mental health conditions.
Citations:
PubMed Identifier
26011054
Citation
Tatham M, Turner H, Mountford VA, Tritt A, Dyas R, Waller G. Development, psychometric properties and preliminary clinical validation of a brief, session-by-session measure of eating disorder cognitions and behaviors: The ED-15. Int J Eat Disord. 2015 Nov;48(7):1005-15. doi: 10.1002/eat.22430. Epub 2015 May 26.
Results Reference
background
PubMed Identifier
7866415
Citation
Fairburn CG, Beglin SJ. Assessment of eating disorders: interview or self-report questionnaire? Int J Eat Disord. 1994 Dec;16(4):363-70.
Results Reference
background
PubMed Identifier
3950219
Citation
Smucker MR, Craighead WE, Craighead LW, Green BJ. Normative and reliability data for the Children's Depression Inventory. J Abnorm Child Psychol. 1986 Mar;14(1):25-39. doi: 10.1007/BF00917219.
Results Reference
background
PubMed Identifier
22193671
Citation
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.
Results Reference
background
PubMed Identifier
23027429
Citation
Horowitz LM, Bridge JA, Teach SJ, Ballard E, Klima J, Rosenstein DL, Wharff EA, Ginnis K, Cannon E, Joshi P, Pao M. Ask Suicide-Screening Questions (ASQ): a brief instrument for the pediatric emergency department. Arch Pediatr Adolesc Med. 2012 Dec;166(12):1170-6. doi: 10.1001/archpediatrics.2012.1276.
Results Reference
background
PubMed Identifier
25157017
Citation
Campbell K, Peebles R. Eating disorders in children and adolescents: state of the art review. Pediatrics. 2014 Sep;134(3):582-92. doi: 10.1542/peds.2014-0194.
Results Reference
background
Links:
URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/018932s017lbl.pdf
Description
Oral naltrexone package insert

Learn more about this trial

Oral Naltrexone In Pediatric Eating Disorders

We'll reach out to this number within 24 hrs